Skip to Main Content

A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma

Conditions

Corpus Uteri

Phase II

What is the purpose of this trial?

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.

  • Trial with
    Yale Cancer Center
  • Start Date
    02/23/2020
  • End Date
    02/28/2024
Trial Image

For more information about this study, contact:

Lisa Baker

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/14/2020
  • Study HIC
    #2000026850